Matches in Nanopublications for { <http://bio2rdf.org/drugbank_resource:DB01030_DB01136> ?p ?o ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- drugbank_resource:DB01030_DB01136 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB01030_DB01136 label "DDI between Topotecan and Carvedilol - The p-glycoprotein inhibitor, Carvedilol, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. [drugbank_resource:DB01030_DB01136]" assertion.
- drugbank_resource:DB01030_DB01136 identifier "drugbank_resource:DB01030_DB01136" assertion.
- drugbank_resource:DB01030_DB01136 title "DDI between Topotecan and Carvedilol - The p-glycoprotein inhibitor, Carvedilol, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided." assertion.